Daily2d
Study finds certain MS therapies may not slow disability progression
In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before ...
Pharmac needs to factor in indirect costs into funding decisions - health economists
An overhaul of the way Pharmac decides to fund drugs for people with chronic long term diseases is needed, say health ...
WebMD24d
FDA Approves First Injectable for Relapsing and Progressive MS
The FDA has approved a new injectable form of the multiple sclerosis drug ocrelizumab for use in adults with relapsing and progressive forms of the disease. Multiple sclerosis occurs when the body ...
NZ Doctor6d
New report calls for major change to Pharmac’s funding model
The report explains that Pharmac’s current funding model is a cost utility analysis (CUA), which is a subset of cost effectiveness analysis. In this, Pharmac weighs up the direct healthcare costs and ...
Science Daily29d
Study finds certain MS therapies may not slow disability progression
About 10 to 15% of people with the disease have this type of MS. The study looked at rituximab and ocrelizumab, anti-CD20 infusion therapies that target a protein called CD20 found on some white ...
Medical Xpress29d
Study finds certain multiple sclerosis therapies may not slow disability progression
About 10 to 15% of people with the disease have this type of MS. The study looked at rituximab and ocrelizumab, anti-CD20 infusion therapies that target a protein called CD20 found on some white ...
Medscape24d
Time to Revisit the Standard Treatment Approach in Kids With MS?
Hacohen reported on a UK cohort of children with MS treated with ocrelizumab, with 66 patients having more than 12 months of follow-up. Of these, only four patients had relapses, and there was no ...
Medical Xpress28d
FDA approves injectable Ocrevus Zunovo for relapsing, progressive multiple sclerosis
The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection for people with ...
The Meningitis Foundation Adds Voice To Calls For Pharmac To Overhaul Its Approach To Funding Decisions
Chair of the Meningitis Foundation, Gerard Rushton says he fully supports MSNZ and its call for Pharmac to adopt a new funding evaluation model that considers more than just the direct healthcare ...
PharmiWeb9d
Perceiv AI Welcomes Simona Skerjanec to Board of Directors
Thought Leader in Brain Health Joins Richard Stark and Company Co-Founders to Accelerate Innovation in Precision MedicineMONTREAL, QC / ACCESSWIRE / October 15, 2024 / Perceiv AI, a leading precision ...
BioSpace13d
Sanofi, Denali Abandon Mid-Stage Multiple Sclerosis Study on Disappointing Data
Oditrasertib, which blocks the inflammatory RIPK1 protein, earlier this year also failed a Phase II trial in amyotrophic ...
News Medical29d
Research questions effectiveness of MS medications in slowing disability progression
About 10 to 15% of people with the disease have this type of MS. The study looked at rituximab and ocrelizumab, anti-CD20 infusion therapies that target a protein called CD20 found on some white ...